
Please try another search
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In addition, it is also developing tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was incorporated in 2011 and is headquartered in Gothenburg, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Charlotte Fribert | 58 | 2016 | CEO & Executive Director |
Kristian Sandberg | 64 | 2017 | Director |
Eva Lindgren | 75 | 2018 | Director |
Maarten Kraan | 64 | 2018 | Director |
Ann-Charlotte Rosendahl | 62 | 2020 | Chair of the Board |
Jan P. Mattsson | 61 | 2020 | Director |
Thomas Eldered | 65 | 2021 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review